Latest Leadership Change News

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

Omnia Metals Group has completed a targeted 941-metre drilling program at its Salt Creek Project, while announcing key leadership changes and preparing for an upcoming General Meeting.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

Mach7 Technologies has updated its FY25 guidance, reporting positive cash flow and a solid financial position, while appointing Teri Thomas as its new CEO to steer the company’s next growth phase.

Mach7 Technologies closes FY25 with solid recurring revenue growth, positive cash flow, and a refreshed leadership team focused on innovation and customer value.

Resolute Mining reported solid Q2 2025 gold production of 75,962 ounces and maintained its full-year guidance, supported by strategic project acquisitions and steady progress across key West African assets.

Wisr Limited has reported a standout Q4FY25 with loan originations soaring 154% year-on-year, surpassing its full-year guidance and showcasing improved credit quality.

Piche Resources has appointed Karilyn Farmer as Managing Director, signaling a strategic push for its gold and uranium assets as founder Stephen Mann retires.

Corazon Mining has completed the sale of its remaining interest in the Miriam Project, appointed Simon Coyle to its board, and continues to push exploration in Canada and Australia amid a strategic review.

Richmond Vanadium Technology has paused parts of its feasibility study and approval processes in response to a prolonged downturn in vanadium prices, focusing instead on metallurgical innovation and cash conservation.

Peninsula Energy advances commissioning at its Lance uranium project, resets most sales contracts to reduce risk, and secures a $15 million debt facility to support production ramp-up.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.